股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年12月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 雲頂新耀有限公司 呈交日期: 2026年1月7日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01952 | 說明 | 普通股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 500,000,000 | USD | | 0.0001 | USD | | 50,000 | | 增加 / 減少 (-) | | | | | | | USD | | | | 本月底結存 | | | 500,000,000 | USD | | 0.0001 | USD | | 50,000 | 本月底法定/註冊股本總額： U ...

Group 1: Neuralink and Brain-Computer Interface Stocks - Neuralink, founded by Elon Musk, plans to start large-scale production of brain-computer interface devices in 2026, leading to a significant surge in related stocks [1] - Nanjing Panda Electronics (00553) saw a rise of over 44%, while other companies like Xinwei Medical-B (06609), Micron Brain Science (02172), and Brainhole Laser-B (06681) increased by 11.90%, 17%, and 19.8% respectively [1] Group 2: Pharmaceutical Sector Performance - The pharmaceutical sector showed strong performance, with China's innovative drug licensing exceeding $100 billion last year [1] - Companies such as Gilead Sciences-B (01672), Cloudtop New Medicine (01952), and Innovent Biologics (01801) experienced stock increases of 8.85%, 5.65%, and 6.28% respectively [1] Group 3: Robotics and Technology Stocks - Woan Robotics (06600) saw its stock rise by over 27%, with a midday increase of 19.57% as it prepares to launch its first humanoid household robot [1] - The company reported a compound annual growth rate of 49% in revenue over the past three years [1] Group 4: Other Notable Stock Movements - Kuaishou-W (01024) increased by over 9%, with foreign investors optimistic about its revenue outlook for next year [1] - Fuhong Hanlin (02696) rose by 7% after three of its innovative cancer drugs received IND acceptance [1] - Kelun-Biotech (06990) gained over 7% following the approval of its clinical trial application for the new drug ITGB6 ADC SKB105 [2] - The Golden Group (03939) increased by 3.94% due to the successful implementation of key projects at the Solomon Gold Mine [3]

Core Viewpoint - CloudTop New Horizon (01952) has initiated a Phase I study to evaluate the safety, tolerability, and preliminary efficacy of EVM14 monotherapy in selected patients with solid tumors, specifically squamous non-small cell lung cancer and head and neck squamous cell carcinoma [2][5]. Group 1: Company Developments - CloudTop New Horizon's stock price increased by 6.02%, currently trading at HKD 40.18, with a trading volume of HKD 136 million [2][5]. - The Phase I trial aims to assess the safety and tolerability of EVM14, determining the recommended Phase II dose (RP2D) [2][5]. Group 2: Clinical Trial Objectives - The primary objective of the trial is to evaluate the safety and tolerability of EVM14 in patients with squamous non-small cell lung cancer and head and neck squamous cell carcinoma [2][5]. - Secondary objectives include assessing the anti-tumor activity of EVM14, while exploratory objectives involve examining the correlation between biomarker expression and efficacy, as well as evaluating immunogenicity, pharmacokinetics, and anti-drug antibodies [2][5]. Group 3: Product Information - EVM14 injection is a biopharmaceutical intended for the treatment of squamous non-small cell lung cancer and head and neck squamous cell carcinoma [2][5]. - Squamous non-small cell lung cancer is a common type of lung cancer characterized by symptoms such as cough and hemoptysis, diagnosed through imaging and pathology [2][5]. - Head and neck squamous cell carcinoma typically originates from mucosal surfaces, presenting with ulcers and masses, and is diagnosed through pathological examination [2][5].

Group 1 - The pharmaceutical stocks are performing strongly, with notable increases in share prices for companies such as Gilead Sciences-B (up 9.9% to HKD 12.66), Kelun-B (up 6.29% to HKD 427.8), and others [1] - As of January 3, the National Medical Products Administration reported that 76 innovative drugs were approved for market in China in 2025, significantly surpassing the 48 approved in 2024, marking a historical high [1] - The total amount of authorized transactions for innovative drugs in China exceeded USD 130 billion in 2025, with over 150 transactions, also setting a new record [1] Group 2 - The 44th J.P. Morgan Healthcare Conference is scheduled to take place from January 12 to 15, 2026, in San Francisco, expected to attract over 8,000 global participants [2] - This conference, which has been held since 1982, will feature over 500 listed companies and thousands of startups, focusing on deep exchanges around "capital + strategy" [2] - The domestic listed pharmaceutical companies are entering a period of innovation, characterized by a dual-driven model of "independent research and development + overseas business development" [2] - Overall, Chinese pharmaceutical companies are shifting from a "single market-driven" approach to "global value creation," with the JPM conference serving as a key platform for showcasing clinical data and negotiating overseas collaborations [2]

Group 1 - The pharmaceutical stocks are experiencing strong performance, with notable increases in share prices for companies such as Genscript Biotech (up 9.9%), Kelun Biotech (up 6.29%), and others [1] - As of January 3, the National Medical Products Administration reported that 76 innovative drugs have been approved for market in China by 2025, significantly surpassing the 48 approved in 2024, marking a historical high [1] - The total amount of authorized transactions for innovative drugs in China is expected to exceed $130 billion in 2025, with over 150 transactions, also a historical high [1] Group 2 - The 44th J.P. Morgan Healthcare Conference is scheduled to take place from January 12 to 15, 2026, in San Francisco, attracting over 8,000 global participants [2] - This conference will feature more than 500 listed companies and thousands of startups, focusing on deep exchanges around "capital + strategy" [2] - Chinese pharmaceutical companies are entering an innovation harvest period, transitioning from a "single market-driven" model to a "global value creation" approach, with the JPM conference serving as a key platform for showcasing clinical data and negotiating overseas collaborations [2]

Core Viewpoint - Genscript Biotech Corporation's stock price increased by approximately 6% following the announcement of the initiation of a Phase I clinical trial for EVM14, a drug aimed at treating squamous non-small cell lung cancer and head and neck squamous cell carcinoma [1] Group 1: Clinical Trial Details - The Phase I study, conducted by Genscript's wholly-owned subsidiary in Beijing, aims to evaluate the safety, tolerability, and preliminary efficacy of EVM14 in selected patients with solid tumors [1] - The primary objective of the trial is to assess the safety and tolerability of EVM14 in patients with squamous non-small cell lung cancer and head and neck squamous cell carcinoma, as well as to determine the recommended Phase II dose (RP2D) [1] - Secondary objectives include evaluating the anti-tumor activity of EVM14, while exploratory objectives involve investigating the correlation between biomarker expression and efficacy, as well as assessing immunogenicity, pharmacokinetics, and anti-drug antibodies [1] Group 2: Drug Information - EVM14 is a biological product intended for the treatment of squamous non-small cell lung cancer and head and neck squamous cell carcinoma [1] - Squamous non-small cell lung cancer is a common type of lung cancer characterized by symptoms such as cough and hemoptysis, diagnosed through imaging and pathology [1] - Head and neck squamous cell carcinoma typically originates from mucosal surfaces and presents with ulcers and masses, diagnosed via pathological examination [1]

Core Viewpoint - Genscript Biotech Corporation's stock price increased by approximately 6% following the announcement of the initiation of a Phase I clinical trial for EVM14, a drug aimed at treating squamous non-small cell lung cancer and head and neck squamous cell carcinoma [1] Group 1: Clinical Trial Details - The Phase I study is being conducted by Genscript Biotech's wholly-owned subsidiary, Genscript Biotech (Beijing) Pharmaceutical Technology Co., Ltd., to evaluate the safety, tolerability, and preliminary efficacy of EVM14 in selected patients with solid tumors [1] - The primary objective of the trial is to assess the safety and tolerability of EVM14 in patients with squamous non-small cell lung cancer and head and neck squamous cell carcinoma, as well as to determine the recommended Phase II dose (RP2D) [1] - Secondary objectives include evaluating the anti-tumor activity of EVM14, while exploratory objectives involve investigating the correlation between biomarker expression and efficacy, as well as assessing immunogenicity, pharmacokinetics, and anti-drug antibodies [1] Group 2: Drug Information - EVM14 injection is a biopharmaceutical product intended for the treatment of patients with squamous non-small cell lung cancer and head and neck squamous cell carcinoma [1] - Squamous non-small cell lung cancer is a common type of lung cancer characterized by symptoms such as cough and hemoptysis, diagnosed through imaging and pathology [1] - Head and neck squamous cell carcinoma typically originates from mucosal surfaces and presents with ulcers and masses, with diagnosis confirmed through pathological examination [1]

热点栏目 自选股 数据中心 行情中心 资金流向 模拟交易 客户端 热点栏目 自选股 数据中心 行情中心 资金流向 模拟交易 客户端 责任编辑：卢昱君 香港联交所最新资料显示，12月31日，董事会主席吴以芳增持云顶新耀（01952）3万股，每股作价 37.98港元，总金额为113.94万港元。增持后最新持股数目约为207.47万股，最新持股比例为0.59%。 责任编辑：卢昱君 香港联交所最新资料显示，12月31日，董事会主席吴以芳增持云顶新耀（01952）3万股，每股作价 37.98港元，总金额为113.94万港元。增持后最新持股数目约为207.47万股，最新持股比例为0.59%。 ...

智通财经APP获悉，香港联交所最新资料显示，12月31日，董事会主席吴以芳增持云顶新耀(01952)3万 股，每股作价37.98港元，总金额为113.94万港元。增持后最新持股数目约为207.47万股，最新持股比例 为0.59%。 ...

Group 1 - The core viewpoint of the news is that Hong Kong's innovative drug concept stocks experienced a collective rise, indicating positive market sentiment in the pharmaceutical sector [1] Group 2 - Jingtai Holdings (02228) saw an increase of 6.13%, with a latest price of 10.040 and a total market capitalization of 43.206 billion [2] - Hengrui Medicine (01276) rose by 4.63%, with a latest price of 74.550 and a total market capitalization of 494.803 billion [2] - SiHuan Pharmaceutical (00460) increased by 4.07%, with a latest price of 1.280 and a total market capitalization of 11.707 billion [2] - Innovent Biologics (01801) experienced a rise of 3.34%, with a latest price of 78.800 and a total market capitalization of 135.599 billion [2] - WuXi Biologics (02269) increased by 3.18%, with a latest price of 32.440 and a total market capitalization of 133.916 billion [2] - China National Pharmaceutical Group (01177) rose by 3.07%, with a latest price of 6.370 and a total market capitalization of 119.506 billion [2] - BeiGene (06160) saw an increase of 2.68%, with a latest price of 184.100 and a total market capitalization of 283.639 billion [2] - Kingstar Bio (01548) rose by 2.66%, with a latest price of 12.750 and a total market capitalization of 27.874 billion [2] - Genscript Biotech (01952) increased by 2.49%, with a latest price of 37.900 and a total market capitalization of 13.4 billion [2] - WuXi AppTec (02359) saw a rise of 2.13%, with a latest price of 100.800 and a total market capitalization of 300.763 billion [2]